<p>總體而言，美國股市在週三想要參與 <strong>Tilray Brands</strong>（TLRY 5.00%）。這家加拿大大麻公司的股票當天上漲了 5%，儘管這主要是由於外部新聞，而非任何內部發展。憑藉這一漲幅，Tilray 輕鬆超越了當天上漲幅度相對較小的 <strong>標準普爾 500 指數</strong>，後者僅上漲了 0.4%。</p>
<h2>可能的替代方案</h2>
<p>像 Tilray 這樣的 marijuana 公司股票價格往往在與該藥物相關的醫學測試結果積極或在美國朝着事實上的合法化邁進時波動。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzgyNDkvcGVyc29uLWluLWxhYi1nZWFyLXdvcmtpbmctd2l0aC1tYXJpanVhbmEtcGxhbnRzLmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzgyNDkvcGVyc29uLWluLWxhYi1nZWFyLXdvcmtpbmctd2l0aC1tYXJpanVhbmEtcGxhbnRzLmpwZyZ3PTcwMA"/></p>
<p>圖片來源：Getty Images。</p>
<p>週三，前一類新聞為將大麻視為醫學有用產品提供了支持。由喬治亞州和科羅拉多州大學的研究人員組成的團隊發現，法律寬鬆的州在處方阿片類藥物方面顯示出 “顯著” 的減少。</p>
<p>儘管阿片類藥物在正確和謹慎使用時是安全的，但許多藥物也非常上癮，因此具有顯著的濫用潛力。</p>
<p>研究人員在分析 2007 年至 2020 年間數百萬美國人的處方索賠的研究中發現，患者被開處方阿片類藥物的比例平均下降了 16%。一些未被識別的州甚至達到了 22%。</p>
<h2>合法化仍然是最佳前進方向</h2>
<p>大麻在某些類型的治療中被證明是有益的程度越高，政治家們就越有理由改革禁止大麻的聯邦法律。這才是真正能夠改變 Tilray 及其眾多掙扎中的大麻行業同行命運的因素。美國各州當前零散的合法化體系並不利於該行業公司的發展。</p>

TLRY

<p>Tilray Brands (TLRY) 的股價上漲了 5%，超過了標準普爾 500 指數 0.4% 的漲幅，這一增長主要受到外部新聞的推動，而非公司內部的發展。喬治亞州和科羅拉多州大學的研究表明，實施寬鬆大麻法律的州在阿片類藥物處方方面平均減少了 16%，這暗示了大麻的潛在醫療益處。這可能有助於支持聯邦合法化的論點，而這對 Tilray 和大麻行業的增長至關重要</p>

<p>As a whole, the U.S. stock market wanted to partake of <strong>Tilray Brands</strong>(TLRY 5.00%) on Wednesday. The Canadian cannabis company's shares enjoyed a 5% lift on the day, although this was due to external news rather than any proprietary development. With that gain, Tilray easily beat the <strong>S&amp;P 500</strong> index, which rose by a relatively light 0.4% that day.</p>
<div class="lb-trans"><p>總體而言，美國股市在週三想要參與 <strong>Tilray Brands</strong>（TLRY 5.00%）。這家加拿大大麻公司的股票當天上漲了 5%，儘管這主要是由於外部新聞，而非任何內部發展。憑藉這一漲幅，Tilray 輕鬆超越了當天上漲幅度相對較小的 <strong>標準普爾 500 指數</strong>，後者僅上漲了 0.4%。</p>
</div><h2>A possible alternative</h2>
<div class="lb-trans"><h2>可能的替代方案</h2>
</div><p>The stock prices of marijuana companies like Tilray tend to move when there are positive results from medical testing related to the drug or some kind of move toward de facto legalization in this country.</p>
<div class="lb-trans"><p>像 Tilray 這樣的 marijuana 公司股票價格往往在與該藥物相關的醫學測試結果積極或在美國朝着事實上的合法化邁進時波動。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzgyNDkvcGVyc29uLWluLWxhYi1nZWFyLXdvcmtpbmctd2l0aC1tYXJpanVhbmEtcGxhbnRzLmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F838249%2Fperson-in-lab-gear-working-with-marijuana-plants.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><p>On Wednesday, a news item in the former category provided support for the treatment of weed as a medically useful product. A team comprised of researchers from the universities of Georgia and Colorado found that states with lenient pot laws have been demonstrating &#34;significant&#34; reductions in the prescribing of opioids.</p>
<div class="lb-trans"><p>週三，前一類新聞為將大麻視為醫學有用產品提供了支持。由喬治亞州和科羅拉多州大學的研究人員組成的團隊發現，法律寬鬆的州在處方阿片類藥物方面顯示出 “顯著” 的減少。</p>
</div><p>Although opioids are safe when used properly and carefully, many are also very addictive and thus have notable potential for abuse.</p>
<div class="lb-trans"><p>儘管阿片類藥物在正確和謹慎使用時是安全的，但許多藥物也非常上癮，因此具有顯著的濫用潛力。</p>
</div><p>The researchers found, in a study analyzing millions of prescription claims from 2007 to 2020 for millions of Americans, that the rate of patients being prescribed opioids declined by 16% on average. Some states it did not identify reached 22%.</p>
<div class="lb-trans"><p>研究人員在分析 2007 年至 2020 年間數百萬美國人的處方索賠的研究中發現，患者被開處方阿片類藥物的比例平均下降了 16%。一些未被識別的州甚至達到了 22%。</p>
</div><h2>Legalization still the best way forward</h2>
<div class="lb-trans"><h2>合法化仍然是最佳前進方向</h2>
</div><p>The more that cannabis can be shown to be beneficial in certain types of treatment, the more justification politicians have for reforming federal law prohibiting it. And that's what's really going to turn around the fortunes of Tilray and its many struggling weed industry peers. The current patchy system of legalization in U.S. states is not conducive to the growth of the sector's companies.</p>
<div class="lb-trans"><p>大麻在某些類型的治療中被證明是有益的程度越高，政治家們就越有理由改革禁止大麻的聯邦法律。這才是真正能夠改變 Tilray 及其眾多掙扎中的大麻行業同行命運的因素。美國各州當前零散的合法化體系並不利於該行業公司的發展。</p>
</div>

為什麼投資者今天對 Tilray Brands 的股票感到興奮